Thrivent Financial for Lutherans
ENTA icon

Thrivent Financial for Lutherans’s Enanta Pharmaceuticals ENTA Stock Holding History

Thrivent Financial for Lutherans’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$359K Hold
28,376
– – ﹤0.01% 2326
2025
Q4 		$448K Sell
28,376
-5,665
-17% -$71.9K ﹤0.01% 2293
2025
Q3 		$407K Sell
34,041
-51,793
-60% -$414K ﹤0.01% 2148
2025
Q2 		$649K Hold
85,834
– – ﹤0.01% 2020
2025
Q1 		$474K Buy
85,834
+41,732
+95% +$258K ﹤0.01% 2096
2024
Q4 		$254K Buy
+44,102
New +$423K ﹤0.01% 2447
2024
Q1 		– Sell
-10,460
Closed -$98K – 2538
2023
Q4 		$98K Sell
10,460
-527
-5% -$4.91K ﹤0.01% 2465
2023
Q3 		$123K Sell
10,987
-39,570
-78% -$637K ﹤0.01% 2407
2023
Q2 		$1.08M Buy
50,557
+4,517
+10% +$133K ﹤0.01% 1759
2023
Q1 		$1.86M Buy
46,040
+26,057
+130% +$1.24M ﹤0.01% 1344
2022
Q4 		$930K Sell
19,983
-155
-0.8% -$7.07K ﹤0.01% 1772
2022
Q3 		$1.04M Buy
20,138
+2,027
+11% +$118K ﹤0.01% 1657
2022
Q2 		$856K Buy
18,111
+3,253
+22% +$177K ﹤0.01% 1802
2022
Q1 		$1.06M Buy
14,858
+216
+1% +$14.1K ﹤0.01% 1796
2021
Q4 		$1.09M Buy
14,642
+99
+0.7% +$7.77K ﹤0.01% 1798
2021
Q3 		$826K Sell
14,543
-150
-1% -$7.42K ﹤0.01% 1945
2021
Q2 		$647K Sell
14,693
-55
-0.4% -$2.69K ﹤0.01% 2086
2021
Q1 		$727K Sell
14,748
-44
-0.3% -$2.19K ﹤0.01% 2050
2020
Q4 		$623K Sell
14,792
-21
-0.1% -$924 ﹤0.01% 2033
2020
Q3 		$678K Buy
14,813
+1,251
+9% +$60.6K ﹤0.01% 1812
2020
Q2 		$681K Buy
13,562
+171
+1% +$8.85K ﹤0.01% 1749
2020
Q1 		$689K Buy
13,391
+668
+5% +$35.6K ﹤0.01% 1531
2019
Q4 		$786K Sell
12,723
-16,794
-57% -$1.04M ﹤0.01% 1619
2019
Q3 		$1.77M Buy
29,517
+17,074
+137% +$1.27M 0.01% 1068
2019
Q2 		$1.05M Buy
12,443
+441
+4% +$39.7K ﹤0.01% 1367
2019
Q1 		$1.15M Buy
12,002
+910
+8% +$81.6K ﹤0.01% 1284
2018
Q4 		$786K Buy
11,092
+243
+2% +$18.6K ﹤0.01% 1314
2018
Q3 		$927K Buy
10,849
+936
+9% +$93.8K ﹤0.01% 1320
2018
Q2 		$1.15M Buy
9,913
+614
+7% +$61.3K ﹤0.01% 1178
2018
Q1 		$752K Buy
9,299
+393
+4% +$30.2K ﹤0.01% 1403
2017
Q4 		$523K Buy
8,906
+176
+2% +$8.81K ﹤0.01% 1660
2017
Q3 		$409K Buy
8,730
+320
+4% +$12.9K ﹤0.01% 1666
2017
Q2 		$303K Buy
8,410
+570
+7% +$18.2K ﹤0.01% 1753
2017
Q1 		$241K Buy
7,840
+380
+5% +$11.8K ﹤0.01% 1800
2016
Q4 		$250K Buy
+7,460
New +$214K ﹤0.01% 1776
2014
Q3 		– Sell
-30,731
Closed -$1.32M – 1867
2014
Q2 		$1.32M Buy
+30,731
New +$1.17M 0.01% 809

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Thrivent Financial for Lutherans's ENTA Position: Q1 2026 in Review

Thrivent Financial for Lutherans held its Enanta Pharmaceuticals (ENTA) position steady in Q1 2026 at 28,376 shares worth $359K. The position accounts for ﹤0.01% of the portfolio, ranked #2326.

Thrivent Financial for Lutherans first reported a position in ENTA in Q2 2014 and has held it in 36 quarters since. The position peaked at $1.86M in Q1 2023. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Thrivent Financial for Lutherans held 28,376 shares of Enanta Pharmaceuticals worth $359K as of Q1 2026.
  • Thrivent Financial for Lutherans left its Enanta Pharmaceuticals share count unchanged in Q1 2026.
  • Enanta Pharmaceuticals made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q1 2026, its #2326 holding.
  • Thrivent Financial for Lutherans first reported a position in Enanta Pharmaceuticals in Q2 2014 and has held it in 36 quarters since.
  • Thrivent Financial for Lutherans's Enanta Pharmaceuticals position peaked at $1.86M in Q1 2023.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.